Information Provided By:
Fly News Breaks for July 28, 2015
TEVA, TEVA, AGN, AGN
Jul 28, 2015 | 04:55 EDT
UBS analyst Marc Goodman raised his price target for Allergan (AGN) to $366 saying he remains bullish on the stock after the company sold its generics business to Teva (TEVA). The sale was a surprise, but you can't blame Allergan management for selling at that price, Goodman told investors yesterday in a research note titled "An Offer They Couldn’t Refuse." He sees "significant upside potential" in shares of Allergan and keeps a Buy rating on the name. The maker of Botox closed yesterday up $18.99 to $327.20.
News For AGN;TEVA From the Last 2 Days
There are no results for your query AGN;TEVA